BIOQ: AI 评分 38/100 — AI 分析 (4月 2026)
Bioqual, Inc. is a preclinical research services company focused on infectious diseases and animal research models. It serves commercial and government clients in the United States.
Key Facts:
AI Score: 38/100
Sector: Healthcare
公司概况
概要：
Bioqual, Inc. is a preclinical research services company focused on infectious diseases and animal research models. It serves commercial and government clients in the United States.
Bioqual, Inc., founded in 1981, provides pre-clinical research services, focusing on in-vivo and in-vitro studies for infectious diseases like COVID-19 and AIDS. Serving both commercial and government clients in the U.S., the company offers specialized assays and animal research models, operating with a market capitalization of $0.03 billion.
BIOQ是做什么的？
Founded in 1981, Bioqual, Inc. is a preclinical research services company providing in-vivo and in-vitro research to commercial and government clients within the United States. The company specializes in research services for a range of infectious diseases, including COVID-19, AIDS, influenza, RSV infection, and flavivirus infections such as Zika and Dengue. Bioqual also conducts research on malaria, hepatitis, and cancer. Bioqual's service offerings include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assays, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation, and other cell-based assays. In addition to its assay services, Bioqual provides animal research model-related services. Headquartered in Rockville, Maryland, Bioqual operates with 278 employees and serves as a critical partner for organizations requiring preclinical research in infectious diseases and related fields. The company's expertise in both in-vivo and in-vitro studies allows it to offer comprehensive research solutions, supporting the development of new therapies and vaccines.
BIOQ的投资论点是什么？
Bioqual, Inc. presents a focused investment opportunity within the preclinical research services sector. The company's specialization in infectious diseases, including COVID-19 and AIDS, positions it to capitalize on ongoing research and development efforts in these areas. With a market capitalization of $0.03 billion and a P/E ratio of 72.91, the company's valuation reflects its growth potential. Key value drivers include continued government and commercial research funding for infectious diseases and expansion of its service offerings. Potential risks include the company's low profit margin of 1.0% and negative gross margin of -0.7%, indicating operational inefficiencies. Investors should monitor the company's ability to improve profitability and capitalize on growth opportunities in the preclinical research market.
BIOQ在哪个行业运营？
Bioqual, Inc. operates within the medical diagnostics and research industry, a segment driven by ongoing advancements in healthcare and increasing demand for preclinical research services. The industry is characterized by intense competition, with companies vying for government and commercial research contracts. Market trends include a growing focus on infectious disease research, driven by global health concerns and the need for new therapies and vaccines. Bioqual's specialization in infectious diseases positions it to capitalize on these trends, although it faces competition from larger and more established players in the market.
Medical - Diagnostics & Research
Healthcare
BIOQ有哪些增长机遇？
- Expansion of COVID-19 Research Services: The ongoing COVID-19 pandemic continues to drive demand for research services related to vaccine and therapeutic development. Bioqual can leverage its expertise in virology and immunology to expand its service offerings in this area. The global market for COVID-19 research is expected to remain robust in the coming years, providing Bioqual with a significant growth opportunity. Timeline: Ongoing.
- Development of New Animal Research Models: Bioqual can develop and commercialize new animal research models for infectious diseases, addressing a critical need in preclinical research. The market for animal research models is estimated to be worth billions of dollars annually, with a growing demand for specialized models that accurately mimic human disease. Timeline: 2-3 years.
- Geographic Expansion: Bioqual can expand its geographic reach by establishing partnerships with research institutions and pharmaceutical companies in new markets. The global market for preclinical research services is growing rapidly, particularly in emerging economies with increasing healthcare investments. Timeline: 3-5 years.
- Strategic Partnerships with Pharmaceutical Companies: Bioqual can form strategic partnerships with pharmaceutical companies to provide preclinical research services for drug development programs. These partnerships can provide Bioqual with a stable source of revenue and access to new technologies and expertise. Timeline: Ongoing.
- Investment in Advanced Technologies: Bioqual can invest in advanced technologies, such as genomics and proteomics, to enhance its research capabilities and offer new services to clients. These technologies can enable Bioqual to provide more comprehensive and sophisticated research solutions, differentiating it from competitors. Timeline: 1-2 years.
- Market capitalization of $0.03 billion, reflecting its small-cap status within the healthcare sector.
- P/E ratio of 72.91, indicating a relatively high valuation compared to earnings.
- Profit margin of 1.0%, suggesting limited profitability and potential operational challenges.
- Gross margin of -0.7%, indicating that the cost of services exceeds revenue generated.
- Beta of -0.07, suggesting low volatility relative to the market.
BIOQ提供哪些产品和服务？
- Provides in-vivo preclinical research services.
- Offers in-vitro preclinical research services.
- Conducts research on infectious diseases such as COVID-19 and AIDS.
- Performs sample processing and virus stock generation.
- Offers virus neutralization and hemagglutination inhibition assays.
- Provides quantitative PCR and ELISA detection assays.
- Conducts flow cytometry and lymphocyte proliferation assays.
- Provides animal research model related services.
BIOQ如何赚钱？
- Generates revenue by providing preclinical research services to commercial clients.
- Generates revenue by providing preclinical research services to government clients.
- Revenue is derived from in-vivo and in-vitro research studies.
- Revenue is earned from specialized assays and animal research models.
- Commercial pharmaceutical companies.
- Government research institutions.
- Biotechnology companies.
- Academic research centers.
- Specialization in infectious disease research provides a niche market.
- Long-standing relationships with government and commercial clients.
- Expertise in both in-vivo and in-vitro preclinical research.
- Proprietary animal research models.
什么因素可能推动BIOQ股价上涨？
- Ongoing: Continued government funding for COVID-19 and infectious disease research.
- Upcoming: Potential partnerships with pharmaceutical companies for drug development programs.
- Upcoming: Development and commercialization of new animal research models.
- Ongoing: Expansion of service offerings in response to emerging infectious diseases.
- Upcoming: Investment in advanced technologies to enhance research capabilities.
BIOQ的主要风险是什么？
- Potential: Changes in government research funding priorities.
- Ongoing: Intense competition from larger research organizations.
- Potential: Economic downturn affecting research budgets.
- Potential: Regulatory changes impacting preclinical research.
- Ongoing: Low profit margin and negative gross margin.
BIOQ的核心优势是什么？
- Specialization in infectious disease research.
- Established relationships with government clients.
- Expertise in in-vivo and in-vitro studies.
- Proprietary animal research models.
BIOQ的劣势是什么？
- Low profit margin.
- Negative gross margin.
- Small market capitalization.
- Limited geographic reach.
BIOQ有哪些机遇？
- Expansion of COVID-19 research services.
- Development of new animal research models.
- Geographic expansion into new markets.
- Strategic partnerships with pharmaceutical companies.
BIOQ面临哪些威胁？
- Intense competition from larger research organizations.
- Changes in government research funding priorities.
- Economic downturn affecting research budgets.
- Regulatory changes impacting preclinical research.
BIOQ的竞争对手是谁？
- Cibus Corp — Focuses on gene editing in agriculture. — (CBSTF)
- Corvus Pharmaceuticals Inc — Develops cancer immunotherapies. — (CORBF)
- Cyclopharm Ltd — Specializes in radiopharmaceutical products. — (CYYNF)
- Distribution Solutions Group Inc — Distributes MRO products. — (DSOL)
- Medical Developments Intl Ltd — Develops pain management products. — (MDDVF)
Key Metrics
- MoonshotScore: 38/100
Company Profile
- CEO: Hanne Andersen-Elyard
- Headquarters: Rockville, US
- Employees: 278
- Founded: 2002
AI Insight
AI analysis pending for BIOQ
- OTC Tier: OTC Other
- Disclosure Status: Unknown
常见问题
What does Bioqual, Inc. do?
Bioqual, Inc. specializes in providing preclinical research services to commercial and government clients, focusing on in-vivo and in-vitro studies. The company conducts research on infectious diseases like COVID-19, AIDS, and influenza, offering services such as sample processing, virus stock generation, and various assays. Bioqual also provides animal research model-related services, playing a critical role in supporting the development of new therapies and vaccines for infectious diseases.
What do analysts say about BIOQ stock?
AI analysis is currently pending for BIOQ. Given the company's OTC Other listing, limited analyst coverage is expected. Investors should focus on the company's fundamentals, including its financial performance, growth prospects, and competitive positioning. Key valuation metrics to consider include the company's market capitalization, P/E ratio, and profit margins. Investors should also assess the risks associated with investing in an OTC stock, including limited liquidity and regulatory oversight.
What are the main risks for BIOQ?
The main risks for Bioqual, Inc. include its low profit margin and negative gross margin, indicating potential operational inefficiencies. As an OTC Other stock, BIOQ faces risks related to limited liquidity, regulatory oversight, and financial disclosure. Changes in government research funding priorities and intense competition from larger research organizations also pose significant challenges. Economic downturns could affect research budgets, impacting Bioqual's revenue and profitability. Investors should carefully consider these risks before investing in BIOQ.